PeerView (PVI) is a leading provider of high-quality, innovative continuing education (CME/CE/CPE and MOC) for clinicians and their interprofessional teams. Combining evidence-based medicine and instructional expertise, PeerView activities improve the knowledge, skills, and strategies that support clinical performance and patient outcomes. PeerView makes its educational programming and expert-led presentations and symposia available through its network of popular podcast channels to support specific specialties and conditions. Each episode includes a link to request CME/CE credit for participation. PeerView is solely responsible for the selection of topics, the preparation of editorial content, and the distribution of all materials it publishes.
http://ww2.peerview.com
Amy Goodrich, NP - Oncology Nurse Insights Into New Agent Classes and Research in B-Cell Lymphoma: Practical Issues and Evidence for the Front-Lines of Care
Go online to PeerView.com/JHB860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this activity, a hematology-oncology nurse expert reviews the latest evidence on novel agent classes and ongoing research in B-cell lymphoma and offers insights on practical issues that nurses caring for patients with B-cell malignancies face in routine practice. Upon completion of this activity, participants will be able to: Review updated efficacy and safety data associated with novel agent classes and other emerging therapies in B-cell lymphoma, including BTK, PI3K, and BCL-2 inhibitors, immunomodulators, antibodies, and CAR-T cell therapy, among others, Cite dosage, administration strategies, and treatment schedules of novel agent classes for the management of newly diagnosed or refractory/relapsed B-cell lymphoma, Apply successful patient educational strategies related to novel therapies and ongoing clinical trials to increase compliance with and adherence to novel regimens for B-cell lymphoma, Utilize effective side effect prevention and management strategies related to novel therapies in patients with B-cell malignancies.